VACCINES - s3-ap-southeast-1.amazonaws.com

www.informaconnect.com.sg/event/vaccines-therapeutics

Addressing the Need for Speed COVID-19 Trials, BioProcess Development, Manufacturing and Commercialisation

28–30 October 2020 | Delivered Digitally

AND THERAPEUTICS 2020

VACCINES

New in 2020!

Global Outlook for Coronavirus and Other Novel Diseases

Investing and Financing Vaccines and Therapeutics Candidates

Regional Projects, Partnerships and Collaboration Opportunities on Vaccines Development

Boosting Capacity of Large-Scale Vaccine Manufacturing

R&D Innovation and Access to The Newest Technology Available in The Market

Case Studies on Candidate Developments, Including COVID-19

ANDREAS SCHMIDTChief Executive Officer,

Proteona, Germany

SANJAY SINGHChief Executive

Officer, Gennova Biopharmaceuticals, India

MIKE WHELANProject Leader, CEPI,

United Kingdom

WU KEChief Executive Officer,

Bravovax, China

PROF NIKOLAI PETRVSKYResearch Director, Vaxine,

Australia

DR. KUMAR VISVANATHANClinical Director of

Medicine & Emergency Services, Co-Director of

the Immunology Research Centre, St. Vincent’s Hospital Melbourne,

Australia

CHAO SHOUBAIChief Operating Officer, Cansino Therapeutics,

China

ANAND GAUTAMExecutive Director &

Emerging Science Lead APAC, Pfizer, Australia

KAYVON MODJARRADDirector, Emerging Infectious Diseases,

US Military HIV Research Program, United States

JEROME BOYD-KIRKUPChief Scientific Officer,

Hummingbird Bioscience, Singapore

MICHAEL AGREZChief Executive Officer

and Chief Scientific Officer, InterK Peptide

Therapeutics Ltd, Australia

DR. JEAN-LOUIS EXCLERProgram Director,

New Initiatives, International Vaccine Institute, South Korea

DR. KENNETH NOONANChief Executive Officer, Lightstone Singapore,

Singapore

GOPINATH NAGESHWARANStrategy and Planning

Lead, Vaccine Epidemiology and Modelling, Sanofi,

Singapore

DR. TAM C. NGUYENDeputy Director of Research,

St. Vincent’s Hospital Melbourne, Associate

Professor, Melbourne Medical School, Adjunct Associate

Professor (Research), Monash School of Public

Health & Preventive Medicine

PROF DEAN HOProvost’s Chair Professor of

Biomedical Engineering and Pharmacology, Director of The N.1 Institute for Health (N.1), Director of Institute for Digital Medicine (WisDM),

Department Head of Biomedical Engineering, National University

of Singapore, Singapore


UNRIVALLED LIST OF VACCINES MANUFACTURERS, RESEARCHERS AND BIOTECHS

DAY ONE: WEDNESDAY 28 OCTOBER 2020


GLOBAL MANUFACTURING CAPABILITIES

13:00 Chairperson’s Opening Remarks

13:00 KEYNOTE ADDRESS Global Pharma Partnerships: Improving Production

Technology and Manufacturing Capabilities Safely — Speeding development timeline

— Meeting nimble manufacturing capacity

— Moving from manufacturing to access

— Managing critical supply chain and logistics deliverables

Supply Chain Senior Representative, Johnson and Johnson, Singapore

13:30 CHINA ADDRESS Ramping Up Coronavirus Vaccines Manufacturing

and Speed to Market — Clinical trials update - Progressing in late-stage

— Increasing manufacturing capacity

— Managing regulations and candidate efficacy

— Safety protocol and vigorously monitoring outcomes

— The case of Ad5-nCoV

Chao Shoubai, Chief Operating Officer, Cansino Therapeutics, China

14:00 In Pursuit of COVID-19 Vaccine – Global Alliance, Funding and a Push for Manufacturing

— CEPI’s role in accelerating alliance, partnership, funding and developing safe vaccines

— Overview of COVID-19 investments

— Expanding and enabling manufacturing capabilities

— Ensuring access, affordability and supply

— What can we expect next?

Mike Whelan, Project Leader, CEPI, United Kingdom

14:30 Networking and Stretch Break

15:00 MANUFACTURING PANEL Reaching for Manufacturing Capacity and a Rapid

Scale-up of Production — Cooperation for speed and scale

— Will tech transfer be critical in succeeding COVID-19 production?

— Ensuring that manufacturing is flexible and fungible

— Manufacturing capacity, capability and investment in process and technology

— Vaccine safety and production optimisation

— Manufacturing infrastructure and capacity

Panellists:

Supply Chain Senior Representative, Johnson and Johnson, Singapore


Michael Agrez, Chief Executive Officer and Chief Scientific Officer, InterK Peptide Therapeutics Ltd, Australia

ACCELERATING VACCINES DEVELOPMENT

15:50 CASE STUDY Accelerating Development and Optimising

Antibodies Development to Existing Treatments — Managing crisis and opportunities during COVID-19

— How to adapt and adjust antibodies developments

— Overcoming the different risks for vaccines

Andreas Schmidt, Chief Executive Officer, Proteona, Germany

16:20 CASE STUDY Developing Therapeutic Antibodies Using Rational

Antibody Discovery — Overview of the therapeutic antibody discovery landscape

— Challenges of classical approaches to monoclonal antibodies (mAb) discovery

— Major benefits of Hummingbird’s approach using its proprietary rational antibody discovery (RAD) platform

— Successes in developing antibodies recognizing precise epitopes on both HER3 and VISTA

Jerome Boyd-Kirkup, Chief Scientific Officer, Hummingbird Bioscience, Singapore

16:50 Upscaling Vaccines Manufacturing Process For speaking enquiry, please contact

[email protected]

17:20 Peptides as Therapeutic and Vaccine Adjuvants in Combating COVID-19

— Modulation of kinase activity

— Th1-skewed immune-boosting response

— Immune dysfunction in the elderly

— Memory cells


18:00 Chairperson’s Summary and End of Day 1

DAY TWO: THURSDAY 29 OCTOBER 2020


R&D INNOVATE


13:00 AUSTRALIAN CASE STUDY Reengineering Existing CoV Candidates for

COVID-19 Vaccines Development — Adapting AI into vaccine development — Tapping on recombinant spike protein

Prof Nikolai Petrvsky, Research Director, Vaxine, Australia

13:30 Effective Vaccine Formulation and Process Development

For speaking enquiry, please contact [email protected]

14:00 CASE STUDY Nanoparticle SARS-CoV-2 Vaccine Development

— Potential of tackling viral diversities — Data collection for safety and efficacy — Ensuring rapid scalability of candidate

Kayvon Modjarrad, Director, Emerging Infectious Diseases, US Military HIV Research Program, United States

14:30 Online Networking and Stretch Break

15:00 The Future is Now: The Role of AI in the Combat with COVID-19

— Collaborating technology in search of cures — How AI has been leveraged in the search for optimal drug combinations to treat COVID-19 patients

— How does IDentif.AI platform make precise recommendations based on dosage and mix

— Key process implementations and what are the challenges faced

— Success rate and key takeaways Prof Dean Ho, Provost’s Chair Professor of Biomedical

Engineering and Pharmacology, Director of The N.1 Institute for Health (N.1), Director of Institute for Digital Medicine (WisDM), Department Head of Biomedical Engineering, National University of Singapore, Singapore

VACCINES TRIALS AND COVID-19

15:30 THE GLOBAL DIALOGUE Reimagining Drug Discovery in The Face of

COVID-19 and Current State of Treatment Trials — What are the key priorities for different region’s global race for COVID-19 vaccine development?

— Government role in trials approval and funding support

— Using adaptive trial design to fast track clinical programs

— The collaboration between countries / institutions on COVID vaccine trials

Panelists:

Dr. Jean-Louis Excler, Program Director, New Initiatives, International Vaccine Institute, South Korea

Dr. Kumar Visvanathan, Clinical Director of Medicine & Emergency Services, Co-Director of the Immunology Research Centre, St. Vincent’s Hospital Melbourne, Australia

Dr. Tam C. Nguyen, Deputy Director of Research, St. Vincent’s Hospital Melbourne, Associate Professor, Melbourne Medical School, Adjunct Associate Professor (Research), Monash School of Public Health & Preventive Medicine, Australia

16:20 INDIA’S CASE STUDY Tackling COVID-19 with Nanotechnology and

mRNA — Accelerating clinical trials

— From India to the rest of the world

— Upscaling production of candidate

Sanjay Singh, Chief Executive Officer, Gennova Biopharmaceuticals, India

16:50 Evidence Generation for Vaccine Safety and Efficacy — Effective evidence generation strategies

— Expediting candidate approval processes

— Correcting misinformation for vaccine use through evidence

Gopinath Nageshwaran, Strategy and Planning Lead, Vaccine Epidemiology and Modelling, Sanofi, Singapore

17:20 Capitalising on Big Data for Better Clinical Outcomes to Speed Up Access for Patients

— Optimising R&D efficiency and speeding up access to patients through big data

— Effective use of big data analytics and how it helps to learn about the virus progresses among diverse patient populations

— What is the paradigm shift towards value and outcomes in the healthcare and pharma system?

Dr. Tam C. Nguyen, Deputy Director of Research, St. Vincent’s Hospital Melbourne, Associate Professor, Melbourne Medical School, Adjunct Associate Professor (Research), Monash School of Public Health & Preventive Medicine, Australia


PARTNERSHIPS AND ALLIANCES


Mike Whelan, Project Leader, CEPI, United Kingdom

13:00 Investor’s Perspective: Assessing the Immunology and Antibodies Market

— Investors’ evolving expectations

— Understanding operational capabilities for value proposition

— Managing portfolio investments

Dr. Kenneth Noonan, Chief Executive Officer, Lightstone Singapore, Singapore

13:30 CASE STUDY International Collaboration for Vaccines

Development — Balancing HIV and COVID candidate’s development

— International data sharing to bridge knowledge gap

— Working together for vaccines deployment

Dr. Jean-Louis Excler, Program Director, New Initiatives, International Vaccine Institute, South Korea

14:00 Partnering for Meaningful Innovation — Innovation and developing cancer vaccines

— Collaboration for Agile Pharma

— Expanding pipelines and technology

Anand Gautam, Executive Director & Emerging Science Lead APAC, Pfizer, Australia

14:30 Online Networking and Stretch Break

15:00 Vaccines Packaging, Distribution, and Storage For speaking opportunities, contact

[email protected]

15:30 Preparing the Supply Chain for Coronavirus Vaccines

— Supply meeting demand: How to ensure sufficient supplies for the world

— Strategies to improve operational efficiency for supply chain

— Optimising vaccine distribution for the public

— Collaboration with stakeholders for speedy vaccines production

Panelists:



Wu Ke, Chief Executive Officer, Bravovax, China More panelists to be confirmed

16:15 Strategic Alliances for Production, Procurement and Distribution of Vaccines

— Critical procurement decision-making

— Advancements in technology and R&D

— Coordinating with international bodies for vaccines supply security

— Working away from inward policy trends for better vaccines distribution

Moderator:

Mike Whelan, Project Leader, CEPI, United Kingdom Panelists:

Andreas Schmidt, Chief Executive Officer, Proteona, Germany

Anand Gautam, Executive Director & Emerging Science Lead APAC, Pfizer, Australia

More panelists to be confirmed


DAY THREE: FRIDAY 30 OCTOBER 2020


Get insights from regional vaccines developers and manufacturers alike as they share market updates, case studies and their thought leadership on key issues such as current vaccines candidacy analysis, R&D and trials insights, private sector investment showcases, government grants and incentives, outlines strategies to scaling up manufacturing and centre staging technological advancements. There will also be focus on vaccines safety, speed to market, affordability, and commercial viability that are pivotal part of vaccine development and delivery.

PARTNERSHIP OPPORTUNITIES AVAILABLEFor more information about how you can leverage on our platform and optimise your marketing budget to reach your target audience, please contact:

Yvonne Leong

Tel: +65 9852 3283 | Email: [email protected]

ABOUT VACCINES AND THERAPEUTICS

WHY ATTEND A DIGITAL EVENT?

WHO WILL YOU MEET?


BY INDUSTRY BY GEOGRAPHY

Pharma & Biotechs

Others

Scientific Reserach& Universities

Regulators, Healthcare Agencies & Associations

CDMO/CROs/CMOs

Tech Solution ProvidersEurope

North Asia

Australia

USA

Other Regions

ASEAN

India

NETWORKING | Connect instantly with full visibility of the participant list via our secure and unique match making platform accessible to all participants, and integrated with the virtual conference.

KNOWLEDGE AND ENGAGEMENT | Same content, but more interactive. Even more opportunities to reach out to fellow participants and speakers using specific tools in our virtual conference platform.

FOCUSED AND TIMELY LEARNING | Receive the latest and most timely trends and figures from leading industry players at your convenience.

CONVENIENCE | With our On Demand Webcasts you can participate from any location, better plan your time and watch what you missed whenever you want.

TIME-EFFICIENT AND COST-SAVING | Save valuable time and money on travelling and accommodation.

REGISTRATIONREGISTER WITH YOUR TEAMS TO ATTEND AND ENJOY

SPECIAL GROUP RATES!

CLICK HERE TO FIND OUT MORE

AND THERAPEUTICS 2020

VACCINESEARLY BIRD RATE

Register & Pay by 4 Sep 2020STANDARD RATE

Register & Pay after 4 Sep 2020

Live Online Experience – Pharma, Biotech Companies Rate SGD $1,595 SGD $1,795

Live Online Experience – Industry Rate SGD $1,895 SGD $2,095

Start-Up Rate SGD $495

GROUP RATE (Per delegate)

PHARMA, BIOTECH COMPANIES RATE

Group of 3 or more SGD $1,195 SGD $1,295

Group of 5 or more SGD $695 SGD $795


INDUSTRY RATE

Group of 3 or more SGD $1,295 SGD $1,495

Group of 5 or more SGD $995 SGD $1,095


SPECIAL CORPORATE RATE STANDARD RATE

Register 25 Passes SGD $5,750

Register 50 Passes SGD $8,995

For terms and conditions, refer to www.informaconnect.com.sg/terms/

FOR GROUP REGISTRATIONS, PLEASE EMAIL [email protected] OR CALL +65 6508 2477

3 EASY WAYS TO REGISTERContact Miki Kong

+65 6508 2477

Registration Enquiry Email

[email protected]

Website


REGISTER NOW


www.informaconnect.com.sg/event/vaccines-therapeutics/#pricing

https://www.informaconnect.com.sg/registration/vaccines-therapeutics/

VACCINES - s3-ap-southeast-1.amazonaws.com

Documents

Transcript of VACCINES - s3-ap-southeast-1.amazonaws.com